España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Comments
Close menu
Loading...
Biogen
BIIB
NASDAQ
Watchlist
Leave a Comment
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$224.29
-2.34
-1.03%
At Close: -
$224.29
0
0.00%
After Hours: 7:10 PM EDT
15 minutes delayed
Get Report
Comment
Q2 2024 Earnings in 9 days from now on Thu Aug 1st, before the market open
Biogen (BIIB) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Biogen (NASDAQ:BIIB) Stock
Biogen Stock (NASDAQ: BIIB)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, July 22, 2024
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Vandana Singh
Wednesday, July 17, 2024
Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data
Zacks
Tuesday, July 16, 2024
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Benzinga Neuro
Friday, July 12, 2024
Key Takeaways From Biogen Analyst Ratings
Benzinga Insights
Piper Sandler Maintains Overweight on Biogen,...
Benzinga Newsdesk
Wednesday, July 03, 2024
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
Vandana Singh
Tuesday, July 02, 2024
Biogen shares are trading lower after the FDA...
Benzinga Newsdesk
Friday, June 28, 2024
Denali Outperforms Industry in 3 Months: Here's Why
Zacks
Needham Reiterates Buy on Biogen, Maintains $...
Benzinga Newsdesk
Reported Earlier, Eisai and Biogen Launch Alz...
Benzinga Newsdesk
Thursday, June 27, 2024
'Biogen Is Pursuing More Dealmaking This Year...
Benzinga Newsdesk
RBC Capital Reiterates Outperform on Biogen, ...
Benzinga Newsdesk
Wednesday, June 26, 2024
Is the Options Market Predicting a Spike in Biogen Stock?
Zacks
Forecasting The Future: 19 Analyst Projections For Biogen
Benzinga Insights
RBC Capital Reiterates Outperform on Biogen, ...
Benzinga Newsdesk
Tuesday, June 25, 2024
'Biogen Has Up To $10B For Its Next M&A Bets'...
Benzinga Newsdesk
Wednesday, June 12, 2024
Biogen Exec Says The Alzheimer's Drug Market ...
Benzinga Newsdesk
Biogen Exec Says LEQEMBI Is Going To Do Very...
Benzinga Newsdesk
Tuesday, June 11, 2024
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
Nabaparna Bhattacharya
Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
Shivani Kumaresan
Monday, June 10, 2024
Eisai And Biogen Announced FDA Accepts Filing...
Benzinga Newsdesk
Friday, June 07, 2024
(BIIB) - Analyzing Biogen's Short Interest
Benzinga Insights
Wednesday, June 05, 2024
RBC Capital Reiterates Outperform on Biogen, ...
Benzinga Newsdesk
Monday, June 03, 2024
Biogen Shares Surge Following Collaboration With Delta Flight Products: What You Need To Know
Vaishali Prayag
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
Biogen shares are trading higher after the co...
Benzinga Newsdesk
Biogen and Delta Flight Products to Collabora...
Benzinga Newsdesk
Friday, May 31, 2024
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
Vandana Singh
Thursday, May 30, 2024
Biogen Announces European Commission Grants M...
Benzinga Newsdesk
Wednesday, May 29, 2024
RBC Capital Reiterates Outperform on Biogen, ...
Benzinga Newsdesk
Monday, May 27, 2024
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
Vandana Singh
Thursday, May 23, 2024
HC Wainwright & Co. Reiterates Buy on Biogen,...
Benzinga Newsdesk
Wednesday, May 22, 2024
Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)
Benzinga Insights
Needham Reiterates Buy on Biogen, Maintains $...
Benzinga Newsdesk
Biogen Has Agreed To Acquire Human Immunology...
Benzinga Newsdesk
Tuesday, May 21, 2024
Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug
Vandana Singh
Monday, May 20, 2024
How Is The Market Feeling About Biogen?
Benzinga Insights
Friday, May 17, 2024
Ionis, Biogen Down on Ending Development of ALS Drug
Zacks
Thursday, May 16, 2024
Truist Securities Maintains Buy on Biogen, Ma...
Benzinga Newsdesk
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Vandana Singh
Shares of Biogen and Ionis Pharmaceuticals ar...
Benzinga Newsdesk
Ionis And Biogen Say Development Of BIIB105 W...
Benzinga Newsdesk
Wednesday, May 15, 2024
Biogen shares are trading higher after partne...
Benzinga Newsdesk
Reported Earlier, Biogen And Eisai Initiated ...
Benzinga Newsdesk
Monday, May 13, 2024
Jim Cramer Likes Micron And Its CEO, Recommends Buying This Big Bank
Avi Kapoor
Friday, May 03, 2024
HSBC Maintains Buy on Biogen, Raises Price Ta...
Benzinga Newsdesk
Monday, April 29, 2024
The Analyst Landscape: 27 Takes On Biogen
Benzinga Insights
Oppenheimer Maintains Outperform on Biogen, M...
Benzinga Newsdesk
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Shanthi Rexaline
Thursday, April 25, 2024
Barclays Maintains Equal-Weight on Biogen, Lo...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
